Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The Advisory Committee on Immunization Practices — an influential group of clinicians and scientists — recommends who should ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

University of Idaho researchers found that the COVID-19 vaccine does not have any adverse effects on a mother’s breast milk.

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

If he’s confirmed as health secretary, Robert F. Kennedy Jr. will have broad authority to pursue an anti-vaccine agenda.

R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...